Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting.
Overview
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06942234 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with 180 participants planned, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSafety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Shares Alphamab Oncology, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Shares Capecitabine, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Shares Capecitabine, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Eribulin, Capecitabine and the tag pipeline.